However, the bar for such therapies will be raised, because instead of treating people who are already seriously ill (and for whom a moderate risk of adverse effects is acceptable), we will be treating people who are still mostly OK, but who are likely to develop Alzheimer's Disease at some point in the future (so we will need very safe treatments).